Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $38.58M rose 11.6% year over year, ahead of the -3.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 1.8% from the prior quarter. Over 3 fiscal years it compounded at +13.5% a year.
Context
- Selling, general & admin amounted to 57.8% of revenue in FY2025, down 35.5 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $7.83B (+5039.9%) for the fiscal year ending Dec 2026, a step up from the -0.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $38.58M-1.8% QoQ
- Last fiscal yearDec 2025
- $152.32M-0.5% YoY
- LTMSep 2026
- $153.2M-3.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 152.32M USD
- Year-over-year change
- -0.5%
- 4-year CAGR
- +16.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 152.32M | -0.5% |
| FY2024 | 2024-12-31 | 153.02M | +43.1% |
| FY2023 | 2023-12-31 | 106.92M | +2.7% |
| FY2022 | 2022-12-31 | 104.1M | +24.4% |
| FY2021 | 2021-12-31 | 83.66M | — |
Selling, General & Admin vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.3% is the 5th highest of 9, against a peer median of +3.6%.
- Selling, general & admin amounts to 40.4% of revenue for IOVA, versus a peer median of 39.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €788.8M EUR | +45.9% | +8.9% | 29.8% | |
| LTM Jun 2026 | $726.99M USD | — | -39.2% | 17.6% | |
| LTM Sep 2026 | $357.49M USD | +10.5% | +25.2% | 26.3% | |
| LTM Sep 2026 | $185.41M USD | +24.0% | +12.7% | 101.6% | |
| LTM Sep 2026 | $153.2M USD | -3.3% | +13.5% | 40.4% | |
| LTM Mar 2026 | $151.41M USD | -3.4% | — | 39.2% | |
| LTM Dec 2025 | $69.65M USD | — | — | — | |
| LTM Sep 2026 | $64.15M USD | +52.3% | +47.5% | — | |
| LTM Mar 2026 | $42.34M USD | -49.3% | -18.0% | 670.4% | |
| LTM Mar 2026 | $21.28M USD | -23.4% | -6.3% | — | |
| LTM Mar 2026 | $17.37M USD | -6.9% | -4.3% | 1736.5% | |
| Peer median (excluding IOVA) | — | +3.6% | +2.3% | 39.2% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.19M | 164.07M | 263.5M |
| Cost of Revenue | 0 | 0 | 10.76M | 124M | 173.18M |
| Gross Profit | 0 | 0 | (9.57M) | 40.08M | 90.32M |
| Gross Margin | — | — | -804.5% | 24.4% | 34.3% |
| Research & Development | 259.04M | 294.78M | 344.08M | 282.34M | 300.27M |
| Selling, General & Admin | 83.66M | 104.1M | 106.92M | 153.02M | 152.32M |
| Operating Expenses | 342.7M | 398.88M | 450.99M | 435.35M | 488.53M |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| EBITDA | (328.27M) | (371.77M) | (414.39M) | (331.4M) | (350.89M) |
| EBITDA Margin | — | — | -34851.9% | -202.0% | -133.2% |
| Operating Income | (342.7M) | (398.88M) | (460.56M) | (395.28M) | (398.21M) |
| Operating Margin | — | — | -38735.0% | -240.9% | -151.1% |
| Interest Income | 451K | 2.99M | 13.04M | 20.27M | 10.31M |
| Interest Expense | 0 | 2.99M | 0 | 0 | 0 |
| Other Income / Expenses | 451K | 2.99M | 13.04M | 20.27M | 5.16M |
| Income Before Tax | (342.25M) | (395.89M) | (447.52M) | (375.01M) | (393.05M) |
| Pre-Tax Margin | — | — | -37638.0% | -228.6% | -149.2% |
| Income Tax Expense | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Net Margin | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (Basic) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| EPS (Diluted) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| Weighted Avg Shares | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
| Weighted Avg Shares (Diluted) | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.